Ex vivo longitudinal profiling of EBV-specific T-cell responses in HL patients and healthy individuals using ELISPOT assays
EBV antigen, patient group . | No. of assays . | Mean SFCs (SE)* . | Median SFCs (IQR)* . | P vs pretherapy . | P vs 6 mo . | P vs 12 mo . | P vs long-term remission . |
|---|---|---|---|---|---|---|---|
| LMP1/2A | |||||||
| ND/RL pretherapy | 87 | 30 (8) | 0 (0-24) | — | — | — | — |
| ND/RL 6 mo | 45 | 87 (24) | 0 (0-106) | .091 | — | — | — |
| ND/RL 12 mo | 41 | 101 (25) | 27 (0-169) | .014† | .494 | — | — |
| Long-term remission | 136 | 153 (33) | 30 (0-176) | < .001† | .07 | .387 | — |
| Healthy | 41 | 102 (40) | 32 (0-94) | .002† | .329 | .996 | .442 |
| EBNA3/4/6 | |||||||
| ND/RL pretherapy | 33 | 221 (77) | 58 (0-187) | — | — | — | — |
| ND/RL 6 mo | 21 | 149 (42) | 60 (40-178) | .651 | — | — | — |
| ND/RL 12 mo | 24 | 351 (93) | 135 (8-135) | .190 | .311 | — | — |
| Long-term remission | 39 | 290 (74) | 106 (14-106) | .258 | .582 | .645 | — |
| Healthy | 43 | 186 (54) | 60 (0-195) | .941 | .621 | .144 | .247 |
| Lytic | |||||||
| ND/RL pretherapy | 16 | 235 (63) | 175 (0-476) | — | — | — | — |
| ND/RL 6 mo | 10 | 389 (165) | 128 (49-916) | .6 | — | — | — |
| ND/RL 12 mo | 13 | 631 (161) | 506 (35-1187) | .076 | .515 | — | — |
| Long-term remission | 23 | 304 (78) | 194 (80-294) | .568 | .71 | .122 | — |
| Healthy | 6 | 245 (51) | 254 (116-367) | .606 | .492 | .237 | .536 |
EBV antigen, patient group . | No. of assays . | Mean SFCs (SE)* . | Median SFCs (IQR)* . | P vs pretherapy . | P vs 6 mo . | P vs 12 mo . | P vs long-term remission . |
|---|---|---|---|---|---|---|---|
| LMP1/2A | |||||||
| ND/RL pretherapy | 87 | 30 (8) | 0 (0-24) | — | — | — | — |
| ND/RL 6 mo | 45 | 87 (24) | 0 (0-106) | .091 | — | — | — |
| ND/RL 12 mo | 41 | 101 (25) | 27 (0-169) | .014† | .494 | — | — |
| Long-term remission | 136 | 153 (33) | 30 (0-176) | < .001† | .07 | .387 | — |
| Healthy | 41 | 102 (40) | 32 (0-94) | .002† | .329 | .996 | .442 |
| EBNA3/4/6 | |||||||
| ND/RL pretherapy | 33 | 221 (77) | 58 (0-187) | — | — | — | — |
| ND/RL 6 mo | 21 | 149 (42) | 60 (40-178) | .651 | — | — | — |
| ND/RL 12 mo | 24 | 351 (93) | 135 (8-135) | .190 | .311 | — | — |
| Long-term remission | 39 | 290 (74) | 106 (14-106) | .258 | .582 | .645 | — |
| Healthy | 43 | 186 (54) | 60 (0-195) | .941 | .621 | .144 | .247 |
| Lytic | |||||||
| ND/RL pretherapy | 16 | 235 (63) | 175 (0-476) | — | — | — | — |
| ND/RL 6 mo | 10 | 389 (165) | 128 (49-916) | .6 | — | — | — |
| ND/RL 12 mo | 13 | 631 (161) | 506 (35-1187) | .076 | .515 | — | — |
| Long-term remission | 23 | 304 (78) | 194 (80-294) | .568 | .71 | .122 | — |
| Healthy | 6 | 245 (51) | 254 (116-367) | .606 | .492 | .237 | .536 |
SE indicates standard error; IQR, interquartile range; —, not applicable.
Arithmetic mean and median values of γ-interferon—producing cells (referred to as spot-forming cells [SFCs] per 106 PBMCs) in response to HLA class 1—restricted LMP1/2, EBNA3/4/6, and lytic antigen peptide epitopes.
Significant P value.